drugset / Trial / NCT05930002

Role of Ivermectin and Colchicine in Treatment of COVID-19: Randomized Controlled Clinical Trial

NCT05930002

Completed 120 enrolled Ain Shams University
RandomizedParallel-groupSingle-blindTreatment

Summary

Corona virus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), a new corona virus that emerged in Wuhan, China, in December 2019. It spread rapidly throughout the world causing great mortality. Till date, there is no specific treatment for COVID-19; Ivermectin and colchicine were proposed as therapeutic options for treatment of COVID-19. Our randomised controlled clinical trial aims to assess the effectiveness of ivermectin and colchicine for treating COVID-19.

Timeline

Start
2021-07-21
Primary completion
2022-09-09
Completion
2022-12-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Colchicine Small molecule 0.5 mg
Comparator Ivermectin Small molecule 0.2 mg/kg Oral
Comparator Cholecalciferol Other / unclassified 2000 iu
Comparator Cholecalciferol Other / unclassified 4000 iu
Comparator Vitamin C Other / unclassified 500 mg
Comparator Zinc Sulfate Unknown 75 mg

Indications